NBP
NovaBridge Biosciences
There isn't enough reported data to score NBP yet.
NBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NBP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NBP PE Valuation
NBP has no meaningful PE right now: it lost money over the past year.
NBP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NBP's losses to grow, with revenue growing.
NBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.22 | -$0.10 |
| Q4 2024 | -$0.12 | +$1.03 |
| Q4 2023 | -$1.15 | +$2.33 |
| Q4 2022 | -$3.48 | -$1.48 |
| Q4 2021 | -$2.00 | -725% |
NBP lost $0.22 per share over the past year, a smaller loss than the year before.
NBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $4.1M | -91% |
| Q4 2022 | $47.8M | +262% |
| Q4 2019 | $4.5M | +189% |
NBP's revenue is growing: $4M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -5302% | -2650 points |
| Q4 2022 | 0% | N/A |
| Q2 2022 | -2019% | +2821 points |
| Q4 2021 | -2652% | -1270 points |
| Q4 2019 | -4840% | -3744 points |
| Q4 2018 | -1383% | N/A |
| Q3 2018 | -587% | N/A |
| Q2 2018 | -1096% | N/A |
NBP's operating margin was −5302% last quarter, down 462 points from the same quarter a year ago, near the bottom of its range since 2018.
NBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$14.6M | +$38.1M |
| Q4 2024 | -$52.7M | +$144.8M |
| Q4 2023 | -$197.5M | +$126.2M |
| Q4 2022 | -$323.7M | -$173.2M |
| Q4 2021 | -$150.5M | -199% |
| Q4 2020 | $152M | +$284.1M |
| Q4 2019 | -$132.1M | -$112.1M |
NBP has burned cash in most quarters: −$73M over the past year, against −$610M the year before.
NBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -17% | -44.9M shares |
| 1 year | +15% | +28.8M shares |
| 3 years | +279% | +162M shares |
NBP has 220M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | $335,000 |
| Q4 2023 | $9.2M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $5.2M |
| Q4 2018 | — |
NBP Net Leverage
NBP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.9 | Oversold |
| Stochastic | 2.9 | Oversold |
NBP's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
NBP PE vs Healthcare Sector
| Metric | NBP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NBP has no meaningful PE right now: it lost money over the past year.
NBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.21 | 31% below |
| 20 week MA | $1.57 | 47% below |
| 50 week MA | $2.36 | 65% below |
| 100 week MA | $2.35 | 65% below |
| 200 week MA | $2.26 | 63% below |
NBP is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
NBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.5 | $41.6 | +232% |
| 2021 | $41.6 | $46.9 | +13% |
| 2022 | $46.9 | $3.48 | -93% |
| 2023 | $3.48 | $1.90 | -45% |
| 2024 | $1.90 | $0.88 | -54% |
| 2025 | $0.88 | $4.34 | +393% |
| 2026 YTD | $4.34 | $0.83 | -81% |
NBP's yearly returns have swung widely, from +393% in 2025 to −93% in 2022. It's down 81% so far in 2026.